Research programme: kinase inhibitors - Pierre Fabre/SGX Pharmaceuticals
Alternative Names: Kinase inhibitors - SGX/UroGeneLatest Information Update: 10 May 2007
At a glance
- Originator SGX Pharmaceuticals; UroGene
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder cancer
Most Recent Events
- 31 Aug 2005 Structural GenomiX is now called SGX Pharmaceuticals
- 23 Dec 2003 Preclinical trials in Bladder cancer in France (unspecified)